Abstract:
A composition comprising scalarane-based sesterterpenes is provided to reduce cholesterol level in the liver by inhibiting activity of FXR(farnesoid X-activated receptor), so that the composition is useful for prevention and treatment of cholesterol metabolism diseases and hyperlipidemia. A composition for preventing and treating diabetes, obesity, hperlipoproteinemia, hyperlipidemia, arteriosclerosis, hypertension, circulatory disease, compulsive overeating and ischemic heart disease comprises scalarane-based sesterterpenes represented by the formula(1), isolated from Spongia sp., wherein the compounds represented by the formula(1) make A/C and B/D chemical bonds with substituents; R1 is hydrogen, hydroxy or acetoxy; and R2 to R4 are each independently methyl, hydroxymethyl or acetoxymethyl.
Abstract:
본 발명은 스칼라레인계 세스터터핀(scalarane-based sesterterpenes) 화합물을 유효성분으로 하는 당뇨병, 비만, 고콜레스테롤혈증, 고리포단백혈증 등의 대사 이상 질환, 고지혈증, 동맥경화증, 고혈압, 순환기계 질환, 과식증, 허혈성 심질환의 예방 또는 치료를 위한 약제학적 조성물 및 건강식품 조성물과 파나소이드 엑스 핵수용체(farnesoid X-activated receptor) 활성 억제제 조성물에 관한 것이며, 상기 스칼라레인계 세스터터핀(scalarane-based sesterterpenes) 화합물은 해면동물인 스폰기아( Spongia sp.)로부터 분리·정제한 것을 특징으로 한다. 본 발명에 따른 조성물은 파나소이드 엑스 핵수용체(farnesoid X-activated receptor; FXR)의 활성을 억제하여 간에서의 콜레스테롤 수치를 효과적으로 낮춤으로써 콜레스테롤 대사 질환 및 고지혈증 치료 및 예방에 유용하다.
Abstract:
A sterol derivative is provided to lower cholesterol level in liver by promoting catabolism of the cholesterol into bile through inhibition of the activity of farnesoid X-activated receptor(FXR), thereby being useful for treating and preventing metabolic diseases and hyperlipidemia. A pharmaceutical composition for preventing or treating diabetes, obesity, hypercholesterinemia, hyperlipoproteinemia, hyperlipidemia, arteriosclerosis, hypertension, cardiovascular disease, compulsive overeating and ischemic heart diseases or for inhibiting the activity of a farnesoid X-activated receptor comprises a sterol derivative represented by a formula(1), wherein the sterol derivative is extracted from Stelodoryx chlorophylla, one of the porifera. In the formula(1), R1 is a group 1 or a group 2.
Abstract:
A pharmaceutical composition comprising scalarane-based sesterterpenes is provided to lower cholesterol level in the liver by inhibiting the activity of farnesoid X-activated receptor, so that the pharmaceutical composition is useful for prevention and treatment of cholesterol metabolism disease and hyperlipemia. A composition for prevention and treatment of cholesterol metabolism disease and hyperlipemia comprises scalarane-based sesterterpenes represented by the formula(1), wherein R1 is hydrogen, hydroxyl or acetoxy; R2 to R4 are each independently methyl, hydroxymethyl or acetoxymethyl; the scalarane-based sesterterpenes are isolated from Spongia sp.; the daily dosage of scalarane-based sesterterpenes is 0.001-400 mg/kg; and the composition is formulated as a pharmaceutical or a health food composition.
Abstract:
본 발명은 하기 화학식 1의 스테롤 계 유도체를 유효성분으로 하는 당뇨병, 비만증, 고콜레스테롤혈증, 고리포단백혈증, 고지혈증, 동맥경화증, 고혈압, 순환기계 질환, 과식증, 허혈성 심질환 예방 또는 치료를 위한 약제학적 조성물, 건강식품 조성물 및 화장품 조성물과 파나소이드 엑스 핵수용체(farnesoid X-activated receptor) 활성 억제제 조성물에 관한 것이다. [화학식 1]
[R 1 은 또는 이다.] 본 발명에 따른 조성물은 파나소이드 엑스 핵수용체(farnesoid X-activated receptor; FXR)의 활성을 억제하여 간에서의 콜레스테롤 수치를 효과적으로 낮춤으로써 콜레스테롤 대사 질환 및 고지혈증 치료 및 예방에 유용하다. 스테롤, 파나소이드 엑스 핵 수용체, 고지혈증, 당뇨병
Abstract:
본 발명은 테오페더린 유도체(Theopederin derivatives) 화합물을 유효성분으로 하는 패혈성 쇼크, 출혈성 쇼크, 류마티즘성관절염, 골관절염, 염증성 장질환, 다발성경화증과 같은 면역 및 자가 면역 질환과 동맥경화, 제2형 당뇨병과 같은 대사성 질환 등의 예방 또는 치료를 위한 약제학적 조성물 및 건강식품 조성물과 유발형산화질소합성효소(iNOS) 활성 억제제 조성물에 관한 것이다. 본 발명에 따른 조성물은 유발형산화질소합성효소(iNOS)의 활성을 억제하여 과도한 양의 일산화질소 생성을 억제함으로써 면역 질환 및 대사성 질환의 치료 및 예방에 유용하다. 테오페더린 유도체, 유발형산화질소합성효소(iNOS)
Abstract:
A pharmaceutical composition comprising theopederin derivatives is provided to inhibit overproduction of nitrogen monoxide by inhibiting the activity of iNOS(inducible nitric oxide synthase), so that the composition is useful for prevention and treatment of immune disease, autoimmune disease and metabolic disorder. A pharmaceutical composition for prevention and treatment of immune disease, autoimmune disease and metabolic disorder comprises theopederin derivatives represented by the formula(1) in which R1 is -CH2OH; and R2 is hydrogen or C1-C5 alkyl group, isolated from the Porifera, wherein the immune disease and autoimmune disease is septic shock, hemorrhagic shock, rheumatoid arthritis, bone arthritis, inflammatory bowel disease or multiple sclerosis; and the metabolic disorder is arteriosclerosis or type 2 diabetes.